文献速递肝病消化道肿瘤与早癌

SGLT2i降低合并2型糖尿病与乙型肝炎病毒感染患者发生肝细胞癌的风险:香港全港队列研究

SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
PubMed 文献 · Hepatology · 2023-04-15

该研究基于香港医院管理局电子数据库,纳入2015至2020年合并2型糖尿病与慢性乙型肝炎感染的患者,按倾向性评分1:1匹配后共2000例(SGLT2i组与非SGLT2i组各1000例,基线时79.7%接受抗乙肝治疗)。随访3704人年期间,SGLT2i组肝细胞癌发病率为1.39例/100人年,非SGLT2i组为2.52例/100人年;SGLT2i使用与肝细胞癌发生风险显著降低相关(HR 0.54,95%CI:0.33-0.88,p=0.013)。

要点

  • 合并2型糖尿病与慢性乙型肝炎感染者中,SGLT2i使用与肝细胞癌发生风险降低相关(HR 0.54,95%CI:0.33-0.88)。
  • SGLT2i组肝细胞癌发病率为1.39例/100人年,非SGLT2i组为2.52例/100人年。
  • 该关联在性别、年龄、血糖控制、糖尿病病程、肝硬化、肝脂肪变、抗乙肝治疗时机及背景降糖药亚组中均相似(交互作用p均>0.05)。

核心结论

  • 在合并2型糖尿病与慢性乙型肝炎感染的患者中,SGLT2i使用与肝细胞癌发生风险降低相关。

研究设计与样本

  • 基于香港医院管理局代表性电子数据库的全港队列研究,纳入2015至2020年合并2型糖尿病与慢性乙型肝炎感染的患者。
  • 按倾向性评分对人口学特征、生化结果、肝脏相关特征及背景用药进行1:1匹配,比较SGLT2i使用组与未使用组。
  • 匹配后共纳入2000例患者,SGLT2i组与非SGLT2i组各1000例,基线时79.7%接受抗乙肝治疗。
  • 采用Cox比例风险回归模型评估SGLT2i使用与肝细胞癌发生的关联。

主要发现

  • 随访共3704人年,SGLT2i组肝细胞癌发病率为1.39例/100人年,非SGLT2i组为2.52例/100人年。
  • SGLT2i使用与肝细胞癌发生风险显著降低相关(HR 0.54,95%CI:0.33-0.88,p=0.013)。
  • 该关联在性别、年龄、血糖控制、糖尿病病程、肝硬化、肝脂肪变、抗乙肝治疗时机及背景降糖药(包括二肽基肽酶-4抑制剂、胰岛素或格列酮类)亚组中均相似(交互作用p均>0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Type 2 diabetes (T2D) and chronic hepatitis B infection (CHB) are risk factors of HCC. Sodium glucose co-transporter 2 inhibitors (SGLT2i) inhibit HCC oncogenesis in preclinical studies. However, clinical studies are lacking. This study aimed to evaluate the impact of SGLT2i use on incident HCC using a territory-wide cohort of exclusively patients with co-existing T2D and CHB. APPROACH AND RESULTS: Patients with co-existing T2D and CHB between 2015 and 2020 were identified from the representative electronic database of the Hong Kong Hospital Authority. Patients with and without SGLT2i use were 1:1 matched by propensity score for their demographics, biochemistry results, liver-related characteristics, and background medications. Cox proportional hazards regression model was used to assess the association between SGLT2i use and incident HCC. A total of 2,000 patients with co-existing T2D and CHB (1,000 in each SGLT2i and non-SGLT2i group; 79.7% on anti-HBV therapy at baseline) were included after propensity-score matching. Over a follow-up of 3,704 person-years, the incidence rates of HCC were 1.39 and 2.52 cases per 100 person-year in SGLT2i and non-SGLT2i groups, respectively. SGLT2i use was associated with a significantly lower risk of incident HCC (HR 0.54, 95%CI: 0.33-0.88, p =0.013). The association remained similar regardless of sex, age, glycemic control, diabetes duration, presence of cirrhosis and hepatic steatosis, timing of anti-HBV therapy, and background antidiabetic agents including dipeptidyl peptidase-4 inhibitors, insulin, or glitazones (all p interaction>0.05). CONCLUSIONS: Among patients with co-existing T2D and CHB, SGLT2i use was associated with a lower risk of incident HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lee CH, Mak LY, Tang EH, et al. SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong. Hepatology. 2023. PMID: 37055020. doi:10.1097/HEP.0000000000000404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。